IOncology

In a significant advancement in cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article "Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial" in JAMA Oncology on April, 2024. This pivotal study investigates the efficacy and safety of MW032, a proposed denosumab biosimilar, in treating solid tumor-related bone metastases. Bone metastases, a common and severe complication in cancer patients, lead to skeletal-related events (SREs) that significantly impact morbidity and mortality. The study addresses the urgent need for more effective and accessible treatments for patients suffering from these severe complications.

In 2023, significant progress has been made in the field of breast cancer research. Dr.  Zefei Jiang from The Fifth Medical Center of  Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article summarizes Professor Jiang's speeches and highlights key advances in breast cancer treatment in 2023.

Editor's Note: In this exclusive interview, we speak with Dr. Anna Dorothea Wagner, a leading expert in gastrointestinal oncology, about the evolving landscape of virtual targeted diagnosis and treatment for…

In 2023, significant progress has been made in the field of breast cancer research. Dr.  Zefei Jiang from The Fifth Medical Center of  Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article delves into Professor Jiang's speeches, exploring the key advancements in breast cancer treatment in 2023.

Editor's note: The LAPIS Phase 3 trial was a large-scale, global, double-blind, placebo-controlled study designed to assess the efficacy of pamrevlumab in combination with chemotherapy for patients with locally advanced…

On July 14, to mark the 40th anniversary of Yunnan Cancer Hospital, the "8th Yunling Breast Cancer Summit Forum," hosted by the Yunnan Anti-Cancer Association and the Chinese Medical Education Association, was held in Kunming. The event gathered cutting-edge advances in breast cancer from domestic and international experts. Dr. Qianjun Chen from Guangdong Provincial Hospital of Traditional Chinese Medicine delivered a keynote report on "Consensus and Controversies in Anti-HER2 Therapy for HER2-Positive Breast Cancer." "Oncology Frontier" interviewed Professor Chen on site to share insights on the consensus and controversies in anti-HER2 therapy for HER2-positive breast cancer, guiding multidisciplinary collaboration to optimize patient management strategies, extend patient survival, and improve quality of life.

The CALYPSO study offers valuable insights into the effectiveness of durvalumab (PD-L1 inhibitor) plus savolitinib (MET inhibitor) (D+S) in MET-driven advanced papillary renal cancer (aPRC). At 41 months follow-up, MET-driven…

The TOPAZ-1 study has provided valuable insights into the role of plasma circulating tumor DNA (ctDNA) testing in detecting clinically actionable alterations (CAAs) in advanced biliary tract cancer (BTC). While…

At SABCS 2024, Dr. Matteo Lambertini shared insights from a major international study examining the role of risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) in young BRCA carriers with breast cancer. The study, which analyzed data from 5,290 patients across 109 centers worldwide, offers a deeper understanding of how these surgeries impact long-term survival.